Plain-English translation of NCT07593976 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new imaging scan called [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT in women with HER2-positive early breast cancer who are receiving chemotherapy before surgery. The scan is designed to light up cancer cells and show whether the chemotherapy is working, which could help doctors predict if surgery will be successful. Researchers hope this imaging tool will eventually help some patients avoid surgery or reduce how much surgery they need.
Right now, doctors can only know for sure if chemotherapy worked by removing the breast tissue during surgery—a procedure that can be physically and emotionally difficult. This trial exists to see if the new imaging scan can reliably predict treatment success without surgery, which could spare some patients from an operation or help doctors plan less invasive approaches.
You likely qualify if…
You likely don't qualify if…
You would receive two imaging scans using the new radioactive tracer: one before you start chemotherapy and another about two weeks before your scheduled surgery. Each scan involves receiving an injection of the imaging agent and then lying still in a scanner for a period of time—similar to a PET or CT scan you may have had before. The trial is taking place at a single cancer center and involves approximately 42 participants total.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
France